ABILIFY ASIMTUFII®

Hold Company

OTSUKA

Learn More

Dosage and Administration

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Specification

720MG/2.4ML (300MG/ML); 960MG/3.2ML (300MG/ML)

Indication

ABILIFY ASIMTUFII® is used in the treatment of adult schizophrenia for bipolar I disorder in adults maintain monotherapy.

Use

Instructions for Use

API

ARIPIPRAZOLE

API Structure

We Supply

ARIPIPRAZOLE

Note:

In-house Standard/EP/USP
Facility GMP
USMF/CDE/CEP

null

Note:

null

null

Note:

null

Drug Patent

Patent No	Expiration Date
10517951	2033/4/23
11097007	2033/4/23
11638757	2033/4/23
8338427	2025/3/15
8399469	2025/6/29

API Patent

Patent No	Expiration Date
8399469	2025/6/29

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.